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Abstract
Aims To characterize and compare the pharmacokinetic
profiles of bromazepam, omeprazole and paracetamol when
administered by the oral and nasogastric routes to the same
healthy cohort of volunteers.
Methods In a prospective, monocentric, randomized cross-
over study, eight healthy volunteers received the three drugs
by the oral (OR) and nasogastric routes (NT). Sequential
plasma samples were analyzed by high-performance liquid
chromatography–UV, pharmacokinetic parameters (Cmax,
AUC01, t½, ke, tmax) were compared statistically, and
Cmax, AUC01 and tmax were analyzed for bioequivalence.
Results A statistically significant difference was seen in the
AUC01 of bromazepam, with nasogastric administration
decreasingavailabilitybyabout25%:AUCOR=2501ng mL
−1h;
AUCNT=1855 ng mL
−1 h (p <0.05); ratio (geometric mean) =
0.74 [90% confidence interval (CI)0.64–0.87]. However, this
does not appear to be clinically relevant given the usual
dosage range and the drug’s half-life (approx. 30 h). A large
interindividual variability in omeprazole parameters prevented
any statistical conclusion from being drawn in terms of both
modes of administration despite their similar average profile:
AUCOR=579 ng mL
−1h; AUCNT=587 ng mL
−1 h (p>0.05);
ratio (geometric mean) = 1.01 (90% CI0.64–1.61). An
extended study with a larger number of subjects may
possibly provide clearer answers. The narrow 90%
confidence limits of paracetamol indicate bioequivalence:
AUCOR=37 μg mL
−1h; AUCNT=41 μg mL
−1h(p >0.05);
ratio (geometric mean) = 1.12 (90% CI0.98–1.28).
Conclusion The results of this study show that the
nasogastric route of administration does not appear to cause
marked, clinically unsuitable alterations in the bioavail-
ability of the tested drugs.
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Introduction
Patient feeding by nasogastric tube has gained increased
significance in recent years, and techniques have improved
concurrently [1–3]. Thus, the number of patient-days for
which nasogastric feeding was provided in our intensive
care unit has grown from 5% in 1986 to 30% in 1995 [4].
In 2000, 3.6% of 1350 patients in our University Hospital
(860 beds) were nourished by means of a nasogastric tube
for an average period of 20 days.
In such patients, the oral route of drug administration has
been quite naturally replaced by the nasogastric route. An
unpublished survey carried out in our hospital showed that
in 2001, 72% of tube-fed patients in the departments of
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otolaryngology, surgery and medicine received their oral
drugs by this route. Of the 29 patients observed, 15 (52%)
were fitted with a nasogastric tube, ten (34%) with a
percutaneous endoscopic gastrostomy and four (14%) with
a jejunostomy. The average number of drugs was 6.5 per
patient (range 1–15). Analgesics represented 16% of all
drugs administered in this manner and antipsychotics 13%.
Most medicines were tablets (59%), followed by efferves-
cent tablets (14%), oral drops (12%) and sirups (10%). As
such, most medicines had to be crushed before being added
to the feeding suspension. However, such an operation is
not suitable for enterosoluble and slow-release tablets.
Furthermore, the oral absorption profile and bioavailability
of drugs could not be guaranteed because they remained
untested; this is without taking into account possible
physicochemical incompatibilities with polymeric material
in the tubes.
Studies addressing this issue are scarce, with the best
investigated drugs to date being theophylline, phenytoin
and antibacterial quinolones. A number of in vitro and in
vivo studies as well as case reports have led to contradic-
tory conclusions for all three of these drugs [5–13]. A
literature review published in 2000 [14] concluded that
phenytoin administration by nasogastric tube led to
decreased absorption and lower than expected plasma
concentrations. However, the conclusions of this survey
seem to ignore the results from four randomized controlled
clinical trials which showed no decrease in absorption. The
bioavailability of theophylline is known to be decreased in
the presence of food. A case report found the same
phenomenon upon administration by nasogastric tube
[15]. However, two subsequent studies have failed to
reproduce this finding and reported an unaffected bioavail-
ability [16, 17]. Antibacterial quinolones, such as cipro-
floxacine and ofloxacine, are well absorbed orally, a fact
suggesting a similar behaviour following administration by
nasogastric tube. Yet a decreased absorption following
administration by the latter route was demonstrated for
ciprofloxacine and ofloxacine [18]. Another study also
found significant losses for ciprofloxacine, ofloxacine and
levofloxacine when these were mixed with an enteral
feeding formulation [19], suggesting that the phenomenon
was a characteristic of this whole class of drugs. In contrast,
the bioavailability of gatifloxacine was found to remain
unaffected when administered together with enteral food in
injured patients [20], as was the absorption of moxiflox-
acine or trovafloxacine in healthy volunteers [21, 22]. An
opposite result was later seen with gatifloxacine in healthy
volunteers [23].
Our review of the literature thus brings to light contra-
dictory results. This may be partly due to large differences
between methodologies, but a salient characteristic in all of
the above studies is that they did not use the same subjects to
compare oral versus nasogastric drug administration. We
have therefore designed a monocentric, prospective, cross-
over and randomized clinical study in healthy volunteers,
with the aim of comparing the pharmacokinetic profile of
drugs administered orally and by the nasogastric route—in
the same subjects. Three drugs were selected for the study
based on their frequent use and relevance in nasally fed
patients, namely paracetamol, bromazepam and omeprazole.
Materials and methods
Subjects and study design
Eight volunteers, four females and four males, aged 21–
27 years, were included in the study. They underwent a
screening visit to assess their eligibility for the trial. Each
volunteer took part in two separate phases of the investi-
gation, one for oral administration and the other for
nasogastric administration. The sequence was randomized,
and the two phases were separated by a 28-day washout
period to avoid intra-individual hormonal differences in the
female subjects. The investigation took place in the
Division of Clinical Pharmacology of our University
Hospital under the constant supervision of at least one
investigator. The protocol was approved by the Ethics
Committee for Clinical Research of the Faculty of Biology
and Medicine of the University of Lausanne.
The nasogastric feeding phase began at 0700 hours. A
polyurethane tube (Freka, Fribourg, Switzerland; length
120 cm, internal diameter 2.1 mm, external diameter
2.8 mm) was placed according to standard procedures.
The subject was then fed continuously for 24 h (30 kcal kg−1
day−1) with an Isosource Energy suspension (1.5 kcal mL−1;
Novartis Pharma, Basel, Switzerland) using a Compat enteral
feeding pump (Novartis). During the first day, the volunteers
were allowed to consume 500 mL of water. On the following
day, a first blood sample was collected from each subject
(labelled as t0). One hour later, each subject was adminis-
tered three drugs separately by the nasogastric route within a
5-min period in the following sequence: one tablet of
Lexotanil 3 mg (bromazepam; Roche Pharma, Reinach,
Switzerland), one tablet of Antramups 20 mg (omeprazole;
AstraZeneca, Zug, Switzerland) and one effervescent tablet
of Dafalgan 1 g (paracetamol; UPSA, Baar, Switzerland).
The tablets were dissolved or suspended in a small volume
of water, with the suspension or solution being instilled with
a syringe into the nasogastric tube. The syringe was rinsed
with 10 mL water between instillations. The Antramups
tablet (Multiple Unit Pellet System) is a disintegrating
formulation containing enteric-coated micropellets (diameter
approx. 500 μm) of omeprazole. The resulting suspension
was administered by nasogastric tube within approximately
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2 min under constant, gentle lateral shaking. The feeding
tube was withdrawn 10 h after nasogastric drug administra-
tion, and the subjects received a standard meal. Blood
samples (10 mL) were collected at 20 and 40 min and 1, 1.5,
2, 3, 4, 6, 8, 12, 24 and 48 h after dosing. The venous
catheter was rinsed with 3 mL NaCl 0.9% after each blood
collection.
On day 1 of the oral administration phase, the volunteers
received standard meals at 0730, 1200 and 1830 hours; no
other food intake was allowed. Beverage intake was limited
to 1.5 L. The second day was the day of drug administra-
tion, which again involved placing a venous catheter and
taking a first blood sample as reference (t0) at 0700 hours.
One hour later, the subject was orally administered one
tablet of Lexotanil 3 mg, one tablet of Antramus 20 mg and
one tablet of Dafalgan effervescent 1 g together with
200 mL water. Blood samples were collected as above.
During this day, the subjects remained supine and received
three standard meals, as on the previous day.
Treatment and analysis of plasma samples
Within minutes of collection, each blood sample was placed
in a CPDA tube and centrifuged at 3200 rpm for 12 min at
4°C. Plasma samples were then divided into 2-mL portions,
which were immediately frozen at −20°C, then at −80°C for
optimal preservation of omeprazole [24].
Determination of the dosage of paracetamol was carried
out by high-performance liquid chromatography (HPLC)
according to a published protocol, using 3-acetaminophenol
as the internal standard [25]. The samples first underwent
solid-phase extraction using Focus columns (6 and 50 mL,
respectively) from Varian (Palo Alto, CA). The columns
were first conditioned with 2 mL of a 50:50 mixture of
methanol and formic acid 2%, then loaded with the plasma
sample (200 μL) and 100 μL of internal standard (10 μg)
and finally washed with 1 mL methanol 5%. The columns
were then extracted with 1 mL methanol; the eluate was
collected in polycarbonate tubes, evaporated under a
nitrogen flux and dissolved into 200 μL eluent.
The quantification of paracetamol was carried out by
HPLC using a Varian instrument equipped with a Prostar
230 pump, a Prostar 410 automatic injector and a Prostar
310 UV detector. The column was a Lichrospher 60 Rp-
Select B (4.0×250 mm, internal diameter 5 μm) equipped
with a LiChroCART 4-4 precolumn (Merck KgaA,
Darmstadt, Germany). A gradient mode was used, starting
with acetonitrile 2% ramped linearly to 50% in 15 min, then
to 55% in 5 min and returning to the initial percentage. The
flow rate was 1.3 mL min−1 and the injection volume was
50 μL. Ultraviolet detection was at 245 nm. The validation
of the method [26] gave a limit of detection of 0.137 ng
mL−1, while the lower and upper limits of quantification
were 0.2 and 40 μg mL−1, respectively. This range was
considered to be satisfactory given the expected concen-
trations {highest plasma concentration following a single
dose (Cmax) 6–22 μg mL
−1 following a single 1000 mg
dose of paracetamol [27–30]}. The lower limit of quanti-
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Fig. 1 Mean concentration curve [with standard deviation (SD) given
by vertical bars] obtained after oral (open circles) or nasogastric (open
triangles) administration of a single 1000 mg dose of paracetamol
effervescent
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Fig. 2 Mean concentration curve (with SD given by vertical bars)
obtained after oral (open circles) or nasogastric (open triangles)
administration of a single 3 mg dose of bromazepam
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Fig. 3 Mean concentration curve (with SD given by vertical bars)
obtained after oral (open circles) or nasogastric (open triangles)
administration of a single 20 mg dose of omeprazole
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fication (0.2 μg mL−1) was also to be considered
satisfactory since such low concentrations are found only
at the end of the terminal elimination phase and have only a
negligible influence on pharmacokinetic parameters, such
as λz, t½ and area under the plasma time concentration
curve (AUC). The precision [coefficient of variation
(CV%)] in inter-and intra-assays was less than 6.3% at all
concentration levels. The accuracy ranged from 95.3 to
101.1% of the mean values.
Bromazepam and omeprazole concentrations were mea-
sured simultaneously using oxazepam as the internal
standard, as previously described [31].
The validation of the method [26] gave a limit of detection
of 4.55 ng mL−1 for bromazepam and 2.01 ng mL−1 for
omeprazole. The lower and upper limits of quantification
were 5 and 100 ng mL−1 for bromazepam and 20 and
2000 ng mL−1 for omeprazole, respectively. The precision
(CV%) in inter- and intra-assays was less than 8.8% (lowest
level) for bromazepam and 14.4% (lowest level) for
omeprazole at all concentration levels. The accuracy ranged
from 96.3 to 99.3% for bromazepam and from 88.3 to
107.9% for omeprazole.
Pharmacokinetic parameters and statistical analysis
The pharmacokinetic analysis was based on a “non-
compartmental” approach. Two pharmacokinetic parameters
were derived directly from the concentration–time curves,
namely Cmax and tmax (time to reach Cmax). The other
parameters were calculated using appropriate equations in the
Excel 2004 V.11.3 program from Microsoft (Richmond, VA):
λz (apparent constant of terminal elimination), t½ (elimination
half-life), AUC01 (area under the curve from zero to t
estimated by the trapezoidal method and log-trapezoidal
method for post-absorption phase, and from t to infinity by
extrapolation), and CL/F (apparent clearance where CL =
clearance and F = bioavailability).
The pharmacokinetic parameters characterizing both
modes of administration were compared statistically and
submitted to a bioequivalence analysis. A log-normal
distribution of values was assumed [32]. Each set of data
was analysed with a quantile–quantile plot (QQ Plot) [33,
34]. When no distribution was apparent, a curve of
cumulated distribution was plotted to complete the analysis
[35]. The log-normality of the various variables could be
confirmed based on the graphical evaluation; a statistical
analysis was thus carried out with a parametric test (t-paired
test) using the logarithm transformation of the data. The
only exception was the discrete variable tmax, which was
analyzed by the non-parametric Wilcoxon’s signed-ranks
test [36]. In both cases, the threshold of significance was
taken to be p=0.05.
A bioequivalence analysis was carried out to assess the
similitude of exposure between the two modes of admin-
istration. The three parameters compared were AUC01,
Cmax and tmax. As recommended by the Federal Drug
Administration and the European Agency for the Evalua-
tion of Medicinal Products [37, 38], the geometric mean,
the CV and the minimal and maximal values were
calculated. Bioequivalence was then assessed by analyzing
the 90% confidence limits (90% CI) around the geometric
mean of the primary parameters (Cmax) and AUC01)
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Fig. 4 Intra- and interindividual variations of the area under the
plasma time–concentration curve (AUC01 ) for the eight subjects
(1–8): a following a single dose of 1000 mg of effervescent
paracetamol orally or by nasogastric tube (NT), b following a single
dose of 3 mg of bromazepam orally and by NT, c following a single
dose of 20 mg of omeprazole orally and by NT
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assuming their log-normal distribution. However, the major
criteria was AUC01 since the time intervals of sampling
did not allow an accurate determination of Cmax and tmax.
The statistical tool R ver.1.16 of the R Foundation for
Statistics (Faculty of Economics, Vienna, Austria) was used
for all analyses [39].
Results
The mean concentration curves (with their standard
deviation, SD) obtained after oral or nasogastric adminis-
tration are shown for paracetamol (1 g dose), bromazepam
(3 mg dose) and omeprazole (20 mg dose) in Figs. 1, 2 and
3, respectively.
Pharmacokinetic parameters of paracetamol
The pharmacokinetic parameters of paracetamol are shown
in Table 1 together with their geometric mean (GeoM) and
CV. The only marginally significant difference between the
oral and nasogastric modes of administration is seen in the
parameters of the elimination phase (λz and t½). The Cmax
values do not satisfy the bioequivalence criterion and are at
the limit of statistical significance (p=0.06), whereas the
tmax values are identical for both modes of administration.
For the AUC01, the 90% CI extends slightly beyond the
recognized criteria of bioequivalence (0.80–1.25). Figure 4a
illustrates the intra- and interindividual variations of
AUC01 for the eight subjects. No clear-cut influence of
the mode of administration can be found, as confirmed by
CV of 25 and 21% for oral and nasogastric administration,
respectively.
Pharmacokinetic parameters of bromazepam
The pharmacokinetic parameters of bromazepam are shown
in Table 2. The parameters of the elimination phase (λz and
t½) do not reveal any meaningful difference between both
modes of administration. The Cmax results suggest a higher
value (p<0.05) after nasogastric administration. Bioequiva-
lence is therefore absent based on CI limits of 0.8–1.25, but
is satisfied within the 0.75–1.33 limits. The 90% CI values
show that the AUC0-last parameter does not fulfil the
criterion of bioequivalence.
Figure 4b illustrates the intra- and interindividual
variations of AUC01 for the eight subjects. An average
decrease of 26% was found for nasogastric administration.
Also, the inter-subject variation is larger after oral admin-
istration (CV 78%).
Pharmacokinetic parameters of omeprazole
The pharmacokinetic parameters of omeprazole are
reported in Table 3. With the exception of λz and t½, no
significant difference was seen between these modes. The
90% CI of Cmax and AUC01 do not satisfy the criteria of
bioequivalence. The mean of the ratios (1.01, p=0.95) does
not indicate that the exposure to the drug is different after
both modes of administration. The CV for oral (172%) and
nasogastric (107%) administration point to an important
interindividual variation, as confirmed by the 90% CI in the
broad range of 0.64–1.61. This variability is also reflected
in the 90% CI of Cmax (0.71–2.16) and in the AUC01
values (Fig. 4c). Interestingly, in six of the eight subjects
nasogastric administration led to slightly lower AUC01
values.
Table 1 Statistic analysis of pharmacokinetic parameters obtained after oral or nasogastric (NA) administration of a single dose of 1000 mg
paracetamol
Parametersa Mode of administration Geometric mean Coefficient of variation
(%)
Ratio geometric mean 90% Confidence interval
Cmax (μg mL
−1) Oral 14.0 22.6
NT 17.7 20.1 1.26 1.04–1.53
tmax (h) Oral 0.41 36.8
NT 0.34 35.4
λz (h
−1) Oral 0.28 13.6*
NT 0.26 14.9
t½ (h) Oral 2.45 13.6*
NT 2.68 14.9
AUC01 (μg mL−1 h) Oral 37.0 25.4
NT 41.3 20.9 1.12 0.98–1.28
CL/F (mL min−1) Oral 451 25.4
NT 403 20.9
*p<0.05
a Cmax, Highest plasma concentration following a single dose; tmax, time to reach Cmax; t½, elimination half-life; λz, apparent constant of terminal
elimination; AUC01, area under the curve from zero to infinity; CL/F, apparent clearance with CL (clearance) and F (bioavailability)
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Discussion
Before discussing individual results, it is important to
outline the risk of bias due to dose effects. Even with a
strictly defined protocol, it was impossible to guarantee that
all subjects received 100% of the nominal dose. As shown
in a preliminary in vitro study, no physicochemical
interaction was seen between the three drugs. However, a
loss of omeprazole of up to 20% was due to residual pellets
after dispersion, dissolution and rinsing. Nevertheless, the
pharmacokinetic analysis was based on the intended
nominal dose, as is customary in clinical trials with
nasogastric tubes.
Prior to the clinical phase, in vitro simulations with
nasogastric tubes were carried out for the three drugs in the
presence and absence of the feeding suspension. No loss of
drug was seen with bromazepam and paracetamol. The
problem was more difficult for omeprazole, and various
methods of administration were examined. Because our
hospital uses Freka 8Fr tubes, the 30-s instillation technique
described by Sostek et al. [40] using 16Fr tubes could not
be applied. Omeprazole was therefore instilled over a 2-min
interval. As already described in the literature [41], we also
observed a loss of drug up to 20%, presumably caused by
the loss of residual pellets even with careful rinsing.
Another issue that requires attention is the small number
of subjects, which limits the statistical impact of the study.
This small number is compensated for by the fact that each
subject was his/her control. Furthermore, in the absence of
any preliminary indications of the magnitude of effects to
be expected, no formal power calculation could be
performed. Our investigation was mainly a pilot study
aimed at determining whether the administration of the test
drugs through a nasogastric tube induced any alteration in
the bioavailability of these drugs that was sufficient to
warrant further study.
Pharmacokinetic parameters of paracetamol
The AUC values extend slightly beyond the rigorous
bioequivalence criterion, but this does not exclude a
bioequivalence between oral and nasogastric administra-
tion. Indeed, in rare cases, a wider acceptance range may be
acceptable, especially if the activity and safety profiles are
well established [36], as is the case for paracetamol. Under
such conditions, a wider bioequivalence criterion (e.g.
0.75–1.33 or even 0.70–1.42) could appear to be justified.
Our results confirm the interest of an effervescent formu-
lation for drug dissolution prior to nasogastric administra-
tion. They are also in line with those of many clinical
investigations that show the lack of an effect of food or
formulation on paracetamol bioavailability. Paracetamol has
also been used as a marker of gastric emptying following
Table 3 Statistic analysis of pharmacokinetic parameters obtained
after oral or nasogastric administration of a single dose of 20 mg
omeprazole
Parameters Mode of
administration
Geometric
mean
Coefficient of
variation (%)
Ratio
GeoM
90%
CI
Cmax
(ng mL−1)
Oral 189 170.2
NT 234 57.2 1.24 0.71–
2.16
tmax (h) Oral 1.33 116.3
NT 1.23 74.0
λz (h
−1) Oral 0.29 172.7*
NT 0.60 61.9
t½ (h) Oral 2.42 172.7*
NT 1.16 61.9
AUC01
(ng mL−1 h)
Oral 579 172.1
NT 587 107.5 1.01 0.64–
1.61
CL/F
(mL min−1)
Oral 576.1 172.1
NT 568 107.5
*p<0.05
Table 2 Statistic analysis of pharmacokinetic parameters obtained after oral or nasogastric administration of a single dose of 3 mg bromazepam
Parameters Mode of administration Geometric mean Coefficient of variation Ratio geometric mean 90% Confidence interval
Cmax (ng mL
−1) Oral 46.0 19.7*
NT 55.1 25.3 1.20 1.10–1.30
tmax (h) Oral 1.53 152.0*
NT 0.53 160.3
λz (h
−1) Oral 0.02 71.9
NT 0.02 40.3
t½ (h) Oral 39.7 71.9
NT 33.3 40.3
AUC01 (ng mL−1 h) Oral 2501 78.0*
NT 1855 56.0 0.74 (0.64–0.87)
CL/F (mL min−1) Oral 20.0 78.0*
NT 27.0 56.0
*p<0.05
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nasogastric feeding. Again, other published results are in
line with those reported here.
Pharmacokinetic parameters of bromazepam
Our results indicate that the nasogastric administration of
bromazepam produces a decrease of about 25% in its
AUC01 compared to oral administration. Given the fact
that Cmax increased while AUC decreased, we postulate that
this decreased AUC is due to an increase in apparent
clearance (CL/F) following nasogastric administration (p=
0.008). Even if this difference is pharmacokinetically real,
its clinical impact should be modest or negligible given the
single-dose administration and Cmax variations, which
remained within the limits of no real therapeutic signifi-
cance. An average value of 2.5 mg mL−1 h (CV=78%) after
an oral administration of 3 mg, as found here, is larger than
that found in other studies, but is close to our finding after
nasogastric administration (1.85 mg mL−1 h, CV=56%).
The half-lives observed after both modes of administration
were comparable, whereas the apparent clearance was
increased after nasogastric administration. By combining
these two observations and knowing that for extravascular
administration the apparent clearance includes absorption
chances, the latter appears to be the most likely cause for
the difference in AUC.
Pharmacokinetic parameters of omeprazole
The plasma concentration curves clearly illustrate large
interindividual variations, as reflected in the CV of the
pharmacokinetic parameters and, in particular, of Cmax and
AUC01. A potential cause for this behaviour may be the
oxidative metabolism of omeprazole as catalysed by
cytochromes P450 2C19 and 3A4. CYP2C19 is known to
show polymorphism (3–5% of poor metabolizers in a
Caucasian population). However, it is difficult to evoke
such a scenario in a small population of eight subjects.
Also, it has repeatedly been shown that intersubject
variability in omeprazole disposition depends on the dose
and duration of administration and is believed to be due to
the pharmacodynamic effect of the drug, namely a major
decrease in gastric acidity, which decreases its breakdown.
The loss of about 20% during administration could also
contribute to the intra- and interindividual variability
observed in omeprazole pharmacokinetics.
Conclusion
Despite the preliminary character of the study and the small
number of subjects involved, taken globally, our results
tend to demonstrate that the nasogastric route represents a
viable mode of administration. Indeed, none of the three
drugs examined showed a systematic and damaging loss in
bioequivalence compared to the oral route. Furthermore, the
nasogastric route seemed to show a smaller interindividual
variation than the oral route. The clearest case was that of
paracetamol, where no statistically significant difference
was found. The AUC of bromazepam showed a fair
intersubject variability, but the clinical impact should be
modest or negligible given the limited range of Cmax
variations. A large intersubject variability was seen for
omeprazole, although no systematic difference in absorp-
tion could be evidenced. An extended study with a larger
number of subjects may perhaps bring clearer answers.
In summary, our study was unable to demonstrate any
clinically significant difference between the oral and
nasogastric routes of administration of paracetamol, bro-
mazepam and omeprazole in healthy volunteers. True
bioequivalence according to standard criteria, however,
remains difficult to establish on a limited number of
subjects. In addition, it is not possible to extrapolate these
conclusions to other classes of drugs, which deserve
separate investigations. Comparative investigations may
also prove useful to evaluate the impact on drug absorption
of other enteric devices, such as tubes for jejunostomy or
percutaneous endoscopic gastroscopy. Because such devi-
ces are invasive, their evaluation in healthy volunteers is
not ethically justifiable and will have to be carried out in
groups of patients. Only by applying this approach will it
be possible to increase our understanding of how gastric
tubes affect medication.
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